@article{oai:tsukuba.repo.nii.ac.jp:02001688,
 author = {Kamat, Ashish M and Shore, Neal and Hahn, Noah and Alanee, Shaheen and 西山, 博之 and NISHIYAMA, Hiroyuki and Shariat, Shahrokh and Nam, Kijoeng and Kapadia, Ekta and Frenkl, Tara and Steinberg, Gary},
 issue = {10},
 journal = {Future Oncology},
 month = {Apr},
 note = {Background: Nonmuscle-invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with high rates of disease recurrence and progression. Current treatment for high-risk NMIBC involves Bacillus Calmette-Guérin (BCG) therapy, but treatment options are limited for patients with recurrent or BCG-unresponsive disease. Aberrant programmed death 1 signaling has been implicated in BCG resistance and bladder cancer recurrence and progression, and pembrolizumab has shown efficacy in patients with BCG-unresponsive high-risk NMIBC. Aim: To describe the rationale and design for the randomized, comparator-controlled Phase III KEYNOTE-676 study, which will evaluate the efficacy and safety of pembrolizumab in combination with BCG in patients with persistent/recurrent high-risk NMIBC after BCG induction therapy.},
 pages = {507--516},
 title = {KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC},
 volume = {16},
 year = {2020},
 yomi = {ニシヤマ, ヒロユキ}
}